BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co P/TBV

The Price to Tangible Book Value (P/TBV) of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 5, 2026 is 7.61. In the previous year, Price to Tangible Book Value (P/TBV) was 8.39 — a change of -9.26% (lower).

P/TBV

7.61

YoY

-9.26%

Last updated:

Price to Tangible Book Value (P/TBV) of BrightGene Bio-Medical Technology Co is 2025 7.61 . Price to Tangible Book Value (P/TBV) of BrightGene Bio-Medical Technology Co was 2024 8.39 . It decreases by -9.26% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
26.55 CNY
Jan 1, 2019
15.19 CNY
Jan 1, 2020
13.87 CNY
Jan 1, 2021
12.07 CNY
Jan 1, 2022
9.12 CNY
Jan 1, 2023
8.46 CNY
Jan 1, 2024
8.39 CNY
Jan 1, 2025
7.61 CNY
The BrightGene Bio-Medical Technology Co P/TBV history
YEARP/TBVYoY
7.61-9.26%
8.39-0.89%
8.46-7.27%
9.12-24.38%
12.07-13.01%
13.87-8.67%
15.19-42.80%
26.55-39.41%
43.83-51.58%
90.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Price to Tangible Book Value (P/TBV) of BrightGene Bio-Medical Technology Co is 7.61 in 2025.

Price to Tangible Book Value (P/TBV) of BrightGene Bio-Medical Technology Co changed from 8.39 to 7.61, representing a -9.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — BrightGene Bio-Medical Technology Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — BrightGene Bio-Medical Technology Co